专题：Inflammatory Myopathies and Dermatomyositis

This cluster of papers covers the epidemiology, classification, and clinical features of inflammatory myopathies such as dermatomyositis and polymyositis. It includes discussions on autoantibodies, interstitial lung disease, cancer risk, treatment strategies, myositis-specific antibodies, juvenile dermatomyositis, and the association with malignancy.
最新文献
A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model

article Full Text OpenAlex

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

article Full Text OpenAlex

Pulmonary alveolar proteinosis developing during tofacitinib treatment for anti–MDA5 antibody–positive dermatomyositis–associated interstitial lung disease: a case report and review of the literature

article Full Text OpenAlex

Spontaneous remission in statin-associated HMGCR-positive immune-mediated necrotizing myopathy after statin withdrawal

article Full Text OpenAlex

Single‐Cell Analysis Reveals Peripheral Helper T Cells in Rheumatoid Arthritis–Related Interstitial Lung Disease

article Full Text OpenAlex

EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia

article Full Text OpenAlex

Thrombotic microangiopathy in a patient with anti-signal recognition particle antibody–positive immune-mediated necrotising myopathy: a case report

article Full Text OpenAlex

Clinical Characteristics and Evolution of Interstitial Lung Disease in Subtypes of Idiopathic Inflammatory Myositis With Prevalent Lung Manifestation: A Retrospective Analysis

article Full Text OpenAlex

Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data

article Full Text OpenAlex

Comment on: Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in systemic sclerosis: a real-world national cohort study

article Full Text OpenAlex

近5年高被引文献
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

article Full Text OpenAlex 247 FWCI35.3611

CD19-targeted CAR T cells in refractory antisynthetase syndrome

letter Full Text OpenAlex 238 FWCI51.1862

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

article Full Text OpenAlex 231 FWCI67.0195

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

article Full Text OpenAlex 217 FWCI46.8299

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells

letter Full Text OpenAlex 189 FWCI48.8496

Trial of Intravenous Immune Globulin in Dermatomyositis

article Full Text OpenAlex 187 FWCI27.4381

Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis

review Full Text OpenAlex 180 FWCI47.2111

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

article Full Text OpenAlex 179 FWCI51.41

Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease

review Full Text OpenAlex 145 FWCI20.22

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

article Full Text OpenAlex 136 FWCI59.7428